| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 11/24/2005 | WO2005111622A2 Diagnostic assay for trypanosoma cruzi infection |
| 11/24/2005 | WO2005111221A1 Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine |
| 11/24/2005 | WO2005111208A1 Method of proliferating plasma cell |
| 11/24/2005 | WO2005111205A1 Tuberculosis vaccine |
| 11/24/2005 | WO2005111201A1 Vaccine comprising an attenuated pestivirus |
| 11/24/2005 | WO2005111199A1 Therapeutic, prophylactic and diagnostic agents for hepatitis b |
| 11/24/2005 | WO2005111198A1 Cancerous disease modifying antibodies |
| 11/24/2005 | WO2005111196A1 Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates |
| 11/24/2005 | WO2005111083A2 Antibodies specific for glycoprotein vi and methods of producing these antibodies |
| 11/24/2005 | WO2005111082A1 Anti-tfr antibody. |
| 11/24/2005 | WO2005111080A2 Methods for reducing biofilm formation in infectious bacteria |
| 11/24/2005 | WO2005111077A2 Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| 11/24/2005 | WO2005111066A2 Polypeptides from non-typeable haemophilus influenzae |
| 11/24/2005 | WO2005110493A2 Methods for delivering mbd peptide-linked agent into cells under conditions of cellular stress |
| 11/24/2005 | WO2005110492A2 Method of using adenoviral vectors to induce an immune response |
| 11/24/2005 | WO2005110490A1 Phospholipase c gamma modulation and uses thereof for management of pain and nociception |
| 11/24/2005 | WO2005110479A2 Treatments for pancreatic cancer |
| 11/24/2005 | WO2005110477A2 Combination therapies for cancer and proliferative angiopathies |
| 11/24/2005 | WO2005110475A2 Antibodies |
| 11/24/2005 | WO2005110474A2 HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| 11/24/2005 | WO2005110473A2 Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| 11/24/2005 | WO2005110472A1 Agent for actively restoring structure and functions of damaged tissues and organs |
| 11/24/2005 | WO2005110471A2 Preparation of salmonella broad-spectrum vaccines |
| 11/24/2005 | WO2005110470A2 Methods and compositions for the modulation of immune responses and autoimmune diseases by activating rp105 (cd180) |
| 11/24/2005 | WO2005110459A2 Method of inducing immunity against stratum corneum chymotrytic enzyme |
| 11/24/2005 | WO2005110454A2 Protective binding members of pyy for the treatment of metabolic disorders |
| 11/24/2005 | WO2005110436A2 Macromolecule-containing sustained release intraocular implants and related methods |
| 11/24/2005 | WO2005110379A2 Pulmonary malarial vaccine |
| 11/24/2005 | WO2005110374A1 Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| 11/24/2005 | WO2005110338A2 Identification of surface-associated antigens for tumor diagnosis and therapy |
| 11/24/2005 | WO2005110013A2 Methods, compositions, and preparations for delivery of immune response modifiers |
| 11/24/2005 | WO2005109991A2 Anti-theileriosis vaccine |
| 11/24/2005 | WO2005080431A3 Monoclonal antibodies that specifically bind to folate receptor alpha |
| 11/24/2005 | WO2005079267A3 Methods for protein production |
| 11/24/2005 | WO2005076003A3 Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp) |
| 11/24/2005 | WO2005070958A3 Lawsonia intracellularis subunit vaccines |
| 11/24/2005 | WO2005052119A3 Adjuvants of immune response |
| 11/24/2005 | WO2005049852A3 Methods and compositions for inducing apoptosis |
| 11/24/2005 | WO2005049077A3 Avian vaccine effective against infectious bursal disease virus |
| 11/24/2005 | WO2005021574A3 Induction of antiviral neutralizing antibodies in humans and animals |
| 11/24/2005 | WO2005000246A3 Methods and compositions for treating rheumatoid arthritis |
| 11/24/2005 | WO2004103271A3 Disease prevention and vaccination prior to thymic reactivations |
| 11/24/2005 | US20050262577 Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer |
| 11/24/2005 | US20050261496 3-(Morpholin-4-ylsulfonyl)-5-(1,3-thiazol-2-yl)-1H-indole-2-carboxamide; inhibiting, modulating and/or regulating signal transduction of both receptor and non-receptor tyrosine kinases; anticarcinogenic, -diabetic, -arhtritic, -inflammatory agents; psoriasis; angiogenesisinhibitors; liver cirrhosis |
| 11/24/2005 | US20050261480 Super humanized antibodies |
| 11/24/2005 | US20050261477 Pharmaceutical compositions and medical treatments comprising notch ligand proteins |
| 11/24/2005 | US20050261476 Peptides for chlamydophila pneumoniae vaccine and diagnosis |
| 11/24/2005 | US20050261338 Beta2-adrenergic receptor agonists |
| 11/24/2005 | US20050261232 Non-natural ribonuclease conjugates as cytotoxic agents |
| 11/24/2005 | US20050261229 Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| 11/24/2005 | US20050261227 Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines |
| 11/24/2005 | US20050261224 Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| 11/24/2005 | US20050261223 Contacting the cell with a small inhibitory RNA (siRNA) that inhibits expression of a RIP140 polypeptide, thereby increasing glucose transport in the cell; eating disoders; metabolism; antidiabetic agents; brown fat |
| 11/24/2005 | US20050261213 Nucleic acid compositions and methods for use |
| 11/24/2005 | US20050261208 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
| 11/24/2005 | US20050261191 neutrophil gelatinase-associated lipocalin (NGAL); siderophore coadministration to enhance secretion |
| 11/24/2005 | US20050261187 Methods and compositions relating to MEK5 and cardiac hypertrophy and dilated cardiomyopathy |
| 11/24/2005 | US20050261186 NRG-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 11/24/2005 | US20050261183 PTHrP-derived modulators of smooth muscle proliferation |
| 11/24/2005 | US20050261178 Administering to patient therapeutic dose of cytokine in combination with antibodies directed against tumor associated antigen carbonic anhydrase IX (CAIX/G250/MN); method characterized in significantly reduced cytokine-related toxicity combined with potentiated effectiveness of anti-G250 antibody alone |
| 11/24/2005 | US20050261166 Compositions and methods for the therapy and diagnosis of lung cancer |
| 11/24/2005 | US20050260734 Packaging cells |
| 11/24/2005 | US20050260731 Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy |
| 11/24/2005 | US20050260621 Immunoreactive 38-KDA ferric binding protein of ehrlichia canis and uses thereof |
| 11/24/2005 | US20050260605 Targeting of genetic vaccine vectors |
| 11/24/2005 | US20050260601 Recombinant mutants of rhabdovirus and methods of use thereof |
| 11/24/2005 | US20050260581 Gonococcal proteins and nucleic acids |
| 11/24/2005 | US20050260579 TGF-beta type receptor cDNAs encoded products |
| 11/24/2005 | US20050260565 contacting in vitro a sample comprising chemokine 88C receptor with a putative ligand, detecting binding of the 88C receptor and the putative ligand; increase in 88C signal transduction activity indicates the ligand is an activator, a decreasein transduction activity indicates the ligand is an inhibitor |
| 11/24/2005 | US20050260560 Administering antigens capable of causing specific immune reaction(s) directed against an infectious agent and/or cells infected with the infectious agent, and decreasing a different specific immune reaction direct towards the infectious agent, infected cells and/or uninfected cells; immunotherapy |
| 11/24/2005 | US20050260258 Use of vitelline protein B as a microencapsulating additive |
| 11/24/2005 | US20050260235 Aids vaccines |
| 11/24/2005 | US20050260234 Anti-neovasculature preparations for cancer |
| 11/24/2005 | US20050260233 Attenuated vaccine useful for immunizations against Coccidioides spp. infections |
| 11/24/2005 | US20050260229 Glycans of Anaplasma marginale major surface protein 1a, pharmaceutical compositions and methods of use |
| 11/24/2005 | US20050260228 Vaccines absorbable by the transmucosal way |
| 11/24/2005 | US20050260227 Novel therapeutic processes for treating cancer with specific antigens |
| 11/24/2005 | US20050260226 Novel therapeutic processes for treating infectious agents by training or adoptive transfer of immune cells, and useful compositions therefor |
| 11/24/2005 | US20050260225 Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens |
| 11/24/2005 | US20050260224 Vaccine based on a cellular penetration factor from an apicomplexan parasite |
| 11/24/2005 | US20050260223 Salmonella vaccine materials and methods |
| 11/24/2005 | US20050260222 Structure-based receptor MIMICS targeted against bacterial superantigen toxins |
| 11/24/2005 | US20050260220 first component is the modified antigenic ectodomain of measles virus hemagglutinin protein, second component fused to first component that binds a surface protein of human immunodeficiency virus; for treating HIV infection and other therapeutic targets against which it is difficult to develop vaccines |
| 11/24/2005 | US20050260219 Carboxypeptidases B from anopheles gambiae. compositions comprising them, vaccine applications and use as therapeutical targets |
| 11/24/2005 | US20050260218 House dust mite allergen, Der f VII, and uses therefor |
| 11/24/2005 | US20050260217 Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof |
| 11/24/2005 | US20050260216 Polypeptide containing a mutation characteristic of an analogous non-human protein; is capable of raising antibodies in human, antibodies bind to both the human protein and the polypeptide |
| 11/24/2005 | US20050260215 Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
| 11/24/2005 | US20050260214 Composition and method for introduction of RNA interference sequences into targeted cells and tissues |
| 11/24/2005 | US20050260213 Fcgamma-RIIB-specific antibodies and methods of use thereof |
| 11/24/2005 | US20050260212 Expressed in the stroma surrounding the cancer tumor, targeting the tumor stroma via anti-LFL2 therapy can decrease the tumor interstitial fluid pressure (IFP), resulting in greater blood flow to the tumor and more efficient chemotherapeutic drug delivery or delivery of other molecular therapy |
| 11/24/2005 | US20050260210 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
| 11/24/2005 | US20050260209 Ephrin-b receptor protein involved in carcinoma |
| 11/24/2005 | US20050260208 Binding agents and their use in targeting tumor cells |
| 11/24/2005 | US20050260207 Monoclonal antibody neutralising cathepsin b activity and uses thereof |
| 11/24/2005 | US20050260206 Drugs containing genetically modified antibody against ganglioside gd3 |
| 11/24/2005 | US20050260205 Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens and therapy thereof |
| 11/24/2005 | US20050260204 interleukin-9 (IL-9); exhibit stability, low to undetectable levels of aggregation; storage stability; autoimmune, inflammatory, proliferative, respiratory diseases |
| 11/24/2005 | US20050260203 Use of fusion polypeptides capable of binding vascular endothelial cell growth factor (VEGF), VEGF family members, and splice variants with specifically desirable characteristics; therapy for ocular diseases |
| 11/24/2005 | US20050260202 Methods for producing proliferating muscle cells |